Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
grade A 3.55 -4.05% -0.15
IMGN closed down 4.05 percent on Monday, March 30, 2020, on 70 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Up
Historical IMGN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.05%
200 DMA Support Bullish -4.05%
20 DMA Support Bullish -4.05%
Inside Day Range Contraction -4.05%
Wide Bands Range Expansion -4.05%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.28%
200 DMA Support Bullish 0.28%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Clinical Medicine Drugs Solid Tumors Monoclonal Antibodies Non Small Cell Lung Cancer Ovarian Cancer Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Antibody Drug Conjugates Clinical Trial Product Metastatic Breast Cancer NHL Amgen Immunogen Its Its Products Metastatic Small Cell Lung Cancer

Is IMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.07
52 Week Low 1.76
Average Volume 3,658,445
200-Day Moving Average 3.39
50-Day Moving Average 4.30
20-Day Moving Average 3.32
10-Day Moving Average 2.96
Average True Range 0.53
ADX 25.08
+DI 22.07
-DI 19.63
Chandelier Exit (Long, 3 ATRs ) 3.24
Chandelier Exit (Short, 3 ATRs ) 3.53
Upper Bollinger Band 4.88
Lower Bollinger Band 1.75
Percent B (%b) 0.57
BandWidth 94.27
MACD Line -0.30
MACD Signal Line -0.45
MACD Histogram 0.1538
Fundamentals Value
Market Cap 318.07 Million
Num Shares 89.6 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -2.91
Price-to-Sales 5.58
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.09
Resistance 3 (R3) 4.10 3.94 4.00
Resistance 2 (R2) 3.94 3.80 3.93 3.97
Resistance 1 (R1) 3.74 3.71 3.66 3.73 3.94
Pivot Point 3.58 3.58 3.54 3.57 3.58
Support 1 (S1) 3.38 3.44 3.30 3.37 3.16
Support 2 (S2) 3.22 3.35 3.21 3.13
Support 3 (S3) 3.02 3.22 3.10
Support 4 (S4) 3.01